Clinical trials: Metastatic Malignant Neoplasm to Brain
Recurrent Medulloblastoma, Refractory Medulloblastoma
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.
- Conditions
- Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
- Trial name
- NCT07698899
- Testing
- 25 mCi 177Lu- DTPA-omburtamab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer Stage IV, Melanoma Stage IV
Screening for Brain Metastases
The survival of patients with CNS metastases often remains limited to some months. CNS metastases are also associated with neurological decline and decrease of quality of life.
- Conditions
- Lung Cancer Stage IV, Melanoma Stage IV, Breast Cancer Metastatic
- Trial name
- GAPIMET (NCT07492121)
- Testing
- gadopiclenol (contrast agent), standard contrast agent
- Where
- Switzerland
- Volunteers
- 180 people
- Sponsor
- University of Zurich
Merkel Cell Carcinoma, Islet Cell Carcinoma
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Merkel Cell Carcinoma, Islet Cell Carcinoma, Neuroendocrine Carcinoma, Pituitary Tumor
- Trial name
- NCT00003514
- Testing
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy
- Where
- United States
- Sponsor
- Burzynski Research Institute
Brain Metastases From Solid Tumors
The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors
This is a prospective, open-label, multicenter, single arm Phase II trial to evaluate the safety, tolerability, intracranial efficacy, pharmacokinetics, and pharmacodynamics of MT027 administered ICV in patients with…
- Trial name
- METAMAX-101 (NCT07897799)
- Testing
- Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
- Where
- 2 sites in United States, Taiwan
- Volunteers
- 40 people
- Sponsor
- T-MAXIMUM Pharmaceutical Inc
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis
Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation
Treatment of non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutation is mainly based on tyrosine kinase inhibitors (TKIs) targeting EGFR.
- Conditions
- Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
- Trial name
- ORBITAL (NCT04233021)
- Testing
- Osimertinib
- Where
- 36 sites in France
- Volunteers
- 57 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Melanoma and Brain Metastases
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
This is a multi-cohort, open label, Phase II study with Dabrafenib (GSK2118436) and Trametinib (GSK1120212) combination therapy in subject with BRAF mutation-positive melanoma that has metastasized to the brain.
- Trial name
- NCT02039947
- Testing
- Dabrafenib, Trametinib
- Where
- 47 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Brain Neoplasms
Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison
This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection.
- Trial name
- GDW (NCT07272616)
- Testing
- Novel Gadolinium-Weighted MRI Sequence
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Stockholm
Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with…
- Trial name
- WAYWIN103 (NCT07206498)
- Testing
- Osimertinib (Tagrisso®), WSD0922-FU
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Wayshine Biopharm, Inc.
Breast Cancer, Triple Negative Breast Cancer
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases…
- Trial name
- NCT06238921
- Testing
- Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain Metastasis
Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases
The purpose of this study is to determine if WBRT combined with SRS resulted in improvements in survival, brain tumor control, functional preservation rate, and frequency of neurologic death.
- Trial name
- NCT00406835
- Testing
- Whole-Brain Radiation Therapy, Stereotactic Radiosurgery
- Where
- Japan
- Volunteers
- 180 people
- Sponsor
- Hokkaido University Hospital
Non-Small Cell Lung Cancer (NSCLC)
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
According to literature reports, about 16.3%-19% of newly diagnosed NSCLC patients are associated with brain metastasis, and 30%-50% of NSCLC patients will develop brain metastasis during the whole course of the disease.
- Trial name
- NCT04905550
- Testing
- Almonertinib, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chongqing University Cancer Hospital
Breast Neoplasms
Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases
The aim of the study is to generate patient-derived organoids (PDOs) from brain resection or biopsied extra-cranial metastases. The preliminary data collected will be used to assess the ability of PDOs to predict patients'…
- Trial name
- PDO (NCT06468124)
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- King's College London
Brain Metastases From Solid Tumors
131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors
The aim of this Proof of Concept study is to determine the therapeutic potential of the L19SIP antibody, labeled with the radionuclide 131I in combination with external beam radiation, for the treatment of patients with multiple…
- Trial name
- NCT01125085
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
- Where
- 10 sites in Italy, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Philogen S.p.A.
Cerebral Edema, Brain Metastases
Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)
Primary Objectives: Pilot Portion: To determine the feasibility and safety of administering oral glyburide to non-diabetic patients receiving stereotactic radiosurgery (SRS) for newly diagnosed brain metastases.
- Trial name
- NCT02460874
- Testing
- Glyburide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Lung Cancer, Breast Cancer
Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases
For patients with 1-6 intraparenchymal brain metastases from various primary histologies (except for melanoma), stereotactic radiosurgery (administered upfront or concurrently) or complete surgical resection with neural stem cell…
- Conditions
- Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT00581113
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Virginia Commonwealth University
Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
A single-center, open-label, non-randomized phase I/II study to evaluate the efficacy, safety and tolerance of crizanlizumab monotherapy and in combination with nivolumab in patients with advanced glioblastoma (GB) who exhausted…
- Conditions
- Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System, MGMT-Unmethylated Glioblastoma
- Trial name
- 14 (NCT05909618)
- Testing
- Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO], Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
- Where
- Israel
- Volunteers
- 33 people
- Sponsor
- Sheba Medical Center
Brain Tumor
Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors
The purpose of the research study is to test new methods that could improve diagnosis and assessment of brain tumors. One of these methods is a new MR (magnetic resonance) imaging technique called magnetic resonance…
- Trial name
- NCT02956291
- Testing
- Magnetic Resonance Fingerprinting
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Case Comprehensive Cancer Center
Brain Metastases, Adult
Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases
The research question is whether a single fraction of preoperative radiosurgery can reduce the incidence of leptomeningeal disease 12 months following resection of a brain metastasis (BM) as compared with 5 fractions of…
- Trial name
- PREOP-2 (NCT05124236)
- Testing
- preoperative radiosurgery, postoperative hypofractionated stereotactic radiotherapy
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 200 people
- Sponsor
- Susanne Rogers
Small Cell Lung Cancer, Brain Metastasis
NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer
The hypothesis of this study is that the addition of NovoTTF-100A System treatment to salvage chemotherapy will significantly increase time to treatment failure in the brain of small cell lung cancer patients.
- Trial name
- NCT02425072
- Testing
- NovoTTF-100A plus chemotherapy
- Where
- United States
- Sponsor
- John Villano
Metastatic Malignant Neoplasm in the Adult Brain, Primary Brain Tumor
Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
This pilot trial studies the brain concentration of eribulin mesylate in treating patients with primary or metastatic brain tumors.
- Trial name
- NCT02338037
- Testing
- Therapeutic Conventional Surgery, Biopsy, Eribulin Mesylate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.